 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well...

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 112,000 shares, a...

Short Interest in Acasti Pharma Inc. (NASDAQ:ACST) Declines By 48.9%

Acasti Pharma Inc. (NASDAQ:ACST  Free Report)  HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for Acasti Pharma in a note issued to investors on Tuesday, October...

Equities Analysts Offer Predictions for Acasti Pharma Inc.'s Q2 2024 Earnings (NASDAQ:ACST)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Acasti Pharma files to sell 6.59M common shares for holders

Virtual Webinar to Take Place October 11, 2023 at 2:00pm ETPRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma...

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...

Acasti Announces $7.5 Million Private Placement Equity Financing

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report)s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.69 and...

Acasti Pharma (NASDAQ:ACST) Shares Cross Below 200 Day Moving Average of $2.69

Acasti Pharma announces $7.5M private placement equity financing

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Acasti Pharma Inc. (NASDAQ:ACST  Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 23,500 shares, an increase of 27.7% from the July 31st total of 18,400 shares. Approximately 0.4% of the ...

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Up 27.7% in August

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.

Watchers	29,000
52-Wk Low	$1.72
52-Wk High	$5.05

Market Cap	$20.4M
Volume (M)	6,647.00
52-Wk High	$5.05
52-Wk Low	$1.72

ACST Acasti Pharma Inc - Ordinary Shares - Class A

About

Feed

News

Earnings

Fundamentals